AI Medical Devices: Approval Status and the Reimbursement Gap | Diagnostics Market Intelligence

Description

List of Tables

Japan has quietly become one of the most prolific approvers of medical AI in the world. Endoscopy AI reached Japanese clinics earlier than almost anywhere else - EndoBRAIN and EndoBRAIN-EYE were the first endoscopy AI approvals in the country, and AI Medical Service's gastroAI-model G became the first PMDA-approved AI for gastric endoscopy - while domestic imaging players Fujifilm, with CAD EYE and REiLI, and Canon Medical, with AiCE deep-learning reconstruction, built approval portfolios alongside them. LPIXEL's EIRL platform added multiple imaging approvals. On paper, Japan looks like an AI medical device success story.

The missing piece is payment. Approval by PMDA establishes that a device is safe and effective; it does not establish that anyone will pay to use it. Most approved medical AI in Japan operates without a dedicated NHI reimbursement line, surviving on institutional budgets, bundled procedure fees, or research funding. The result is a reimbursement gap: adoption that depends on hospital goodwill rather than on a payment signal. The FY2028 medical fee revision is the next opportunity to close that gap, and the evidence being assembled now - workflow studies, outcome data, economic analyses - will determine which AI categories arrive at that revision with a credible case and which do not. International precedents sharpen the question: Viz.ai's stroke triage and HeartFlow's FFR-CT have secured dedicated payment routes in the US, and China's NMPA has granted Class III approvals to imaging AI from Shukun, Airdoc, and Infervision, creating a reimbursement debate of its own.

This report maps the approval landscape and the reimbursement gap for AI medical devices in Japan. It catalogs the approved products by modality - endoscopy, CT, fundus, pathology, ultrasound - profiles the developers and their evidence strategies, and reconstructs the fee-schedule mechanics through which AI could be paid: new technology assessments, functional add-ons, and procedure-fee integration. A dedicated chapter defines the evidence bar for the FY2028 revision and what each AI category still needs to clear it. Comparative chapters examine US payment precedents, European CE-marked AI from Gleamer and others, and China's NMPA approval wave.

The report serves AI health companies planning Japan strategy, investors pricing regulatory and reimbursement risk, hospital groups evaluating adoption, and policy analysts tracking the fee-revision cycle. Annual updates track each approval and each reimbursement development.

Scope and Coverage: The report covers PMDA-approved and pipeline AI medical devices in Japan across imaging, endoscopy, pathology, and triage categories, the NHI reimbursement status of AI, and the evidence requirements heading into the FY2028 revision, with comparators from the US, EU, and China. It does not assess the clinical performance of individual algorithms.

Report Highlights:

Complete map of PMDA AI approvals by modality and developer
Reimbursement gap analysis: how approved AI is paid for today and the FY2028 evidence bar
Profiles of AI Medical Service, Cybernet Systems, Fujifilm, Canon Medical, LPIXEL, and Olympus
International payment precedents from Viz.ai, HeartFlow, and Paige
China NMPA Class III AI approval wave covering Shukun, Airdoc, and Infervision
Fee-schedule mechanics through which AI categories could gain dedicated payment

Product Code: JPH-063

Table of Content

1. Executive Summary

2. AI Medical Devices: Technology and Test Landscape

3. Clinical Evidence and Guideline Context

4. Regulatory Status: PMDA, FDA, IVDR, and NMPA Pathways

5. Reimbursement and Price Formation with a Focus on Japan

6. Adoption, Channels, and Screening Infrastructure in Japan

7. Competitive Landscape: Companies and Platforms

8. Opportunities and Barriers for Market Participants

9. Appendix: Methodology and Sources

Companies Mentioned

AI Medical Service (JP) - gastroAI-model G, first PMDA-approved AI for gastric endoscopy
Fujifilm (JP) - CAD EYE endoscopy AI and REiLI imaging AI
Canon Medical (JP) - AiCE deep-learning reconstruction and imaging AI
Siemens Healthineers (DE) - AI-Rad Companion imaging AI suite
GE HealthCare (US) - imaging and ultrasound AI portfolio
Shukun Technology (CN) - NMPA Class III AI approvals across CT and DR modalities
Olympus (JP) - endoscopy AI partnerships and CAD EYE distribution
Cybernet Systems (JP) - EndoBRAIN and EndoBRAIN-EYE, first endoscopy-AI approvals in Japan
LPIXEL (JP) - EIRL imaging AI platform with multiple PMDA approvals
Viz.ai (US) - stroke triage AI with US reimbursement precedents
HeartFlow (US) - FFR-CT analysis with dedicated CPT codes
Paige (US) - FDA-authorized pathology AI
Gleamer (FR) - radiology AI with CE marks across trauma and chest
Airdoc (CN) - first NMPA Class III fundus AI (Aug 2020), multi-condition retinal screening
Infervision (CN) - NMPA- and FDA-cleared chest imaging AI

Product Code: JPH-063

List of Tables

Table 1. PMDA AI medical device approval framework and SaMD classification
Table 2. Approved AI devices in Japan by modality
Table 3. AI Medical Service gastroAI-model G approval for gastric endoscopy
Table 4. Cybernet Systems EndoBRAIN and EndoBRAIN-EYE approval history
Table 5. Fujifilm CAD EYE endoscopy AI positioning
Table 6. Fujifilm REiLI imaging AI portfolio
Table 7. Canon Medical AiCE deep-learning reconstruction
Table 8. LPIXEL EIRL imaging AI platform approvals
Table 9. Olympus endoscopy AI partnerships and CAD EYE distribution
Table 10. Siemens Healthineers AI-Rad Companion suite
Table 11. GE HealthCare imaging and ultrasound AI portfolio
Table 12. Viz.ai stroke triage AI and US reimbursement precedents
Table 13. HeartFlow FFR-CT analysis and dedicated CPT codes
Table 14. Paige FDA-authorized pathology AI
Table 15. Gleamer CE-marked radiology AI portfolio
Table 16. Shukun Technology NMPA Class III approvals across CT and DR
Table 17. Airdoc NMPA Class III fundus AI approval (August 2020)
Table 18. Infervision NMPA- and FDA-cleared chest imaging AI
Table 19. Endoscopy AI evidence packages used in Japanese approvals
Table 20. Imaging AI evidence packages used in Japanese approvals
Table 21. Current NHI payment status of approved AI devices
Table 22. Institutional budget models supporting AI adoption
Table 23. Functional add-on fee mechanisms relevant to AI
Table 24. New medical technology assessment pathway for AI
Table 25. Procedure-fee integration options for AI-assisted diagnosis
Table 26. FY2028 revision evidence requirements by AI category
Table 27. Workflow and time-saving study designs for AI evidence
Table 28. Outcome study designs for AI reimbursement evidence
Table 29. Economic evaluation frameworks for medical AI
Table 30. Academic society positions on AI reimbursement
Table 31. Insurance-covered versus self-paid AI applications
Table 32. Pathology AI approval and payment status
Table 33. Triage and alerting AI approval status
Table 34. Ultrasound AI development landscape
Table 35. Fundus AI screening applications in Japan
Table 36. US AI payment mechanisms: CPT codes, NTAP, and coverage policies
Table 37. European AI payment landscape by country
Table 38. China AI medical device approval and payment landscape
Table 39. Comparative approval-to-payment lag across markets
Table 40. AI device post-market performance monitoring requirements
Table 41. Change-management rules for learning algorithms in Japan
Table 42. Data requirements for AI training and validation in Japan
Table 43. Partnership models between AI developers and modality OEMs
Table 44. Hospital procurement behavior for AI software
Table 45. Radiology and endoscopy workforce context for AI adoption
Table 46. Investment landscape for Japanese medical AI developers
Table 47. Entry sequencing for foreign AI companies into Japan
Table 48. Scenario framework for the FY2028 AI reimbursement outcome
Table 49. Stakeholder map for AI reimbursement policy
Table 50. Report methodology and annual update design

List of Figures

Figure 1. PMDA AI approval framework structure
Figure 2. Approved AI device map by modality
Figure 3. AI Medical Service gastroAI-model G development pathway
Figure 4. Cybernet Systems EndoBRAIN approval lineage
Figure 5. Fujifilm CAD EYE workflow in endoscopy
Figure 6. Fujifilm REiLI imaging AI architecture
Figure 7. Canon Medical AiCE reconstruction workflow
Figure 8. LPIXEL EIRL platform approval map
Figure 9. Olympus AI partnership structure
Figure 10. Siemens AI-Rad Companion suite composition
Figure 11. GE HealthCare AI portfolio map
Figure 12. Viz.ai US payment precedent pathway
Figure 13. HeartFlow FFR-CT payment precedent pathway
Figure 14. Paige pathology AI authorization pathway
Figure 15. Gleamer CE-marked portfolio map
Figure 16. Shukun Technology NMPA approval map
Figure 17. Airdoc fundus AI approval lineage
Figure 18. Infervision cross-region clearance map
Figure 19. Endoscopy AI evidence package anatomy
Figure 20. Imaging AI evidence package anatomy
Figure 21. Current payment status map for approved AI
Figure 22. Institutional budget funding model for AI
Figure 23. Functional add-on fee mechanism diagram
Figure 24. New technology assessment pathway for AI
Figure 25. Procedure-fee integration options diagram
Figure 26. FY2028 evidence bar by AI category
Figure 27. Workflow study design framework
Figure 28. Outcome study design framework
Figure 29. Economic evaluation framework for medical AI
Figure 30. Academic society engagement map
Figure 31. Insured versus self-paid AI application map
Figure 32. Pathology AI approval status structure
Figure 33. Triage AI deployment workflow
Figure 34. Ultrasound AI development map
Figure 35. Fundus AI screening pathway
Figure 36. US AI payment mechanism map
Figure 37. European AI payment landscape map
Figure 38. China AI approval and payment structure
Figure 39. Approval-to-payment lag comparison
Figure 40. Post-market monitoring requirements for AI
Figure 41. Change-management rules for adaptive algorithms
Figure 42. Training and validation data requirement structure
Figure 43. AI developer and modality OEM partnership archetypes
Figure 44. Hospital AI procurement process
Figure 45. Workforce context for AI adoption
Figure 46. Japanese medical AI investment landscape
Figure 47. Foreign AI entry sequencing options
Figure 48. Scenario tree for FY2028 AI reimbursement
Figure 49. Stakeholder influence map in AI payment policy
Figure 50. Report scope, method, and annual update design

AI Medical Devices: Approval Status and the Reimbursement Gap | Diagnostics Market Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. AI Medical Devices: Technology and Test Landscape

3. Clinical Evidence and Guideline Context

4. Regulatory Status: PMDA, FDA, IVDR, and NMPA Pathways

5. Reimbursement and Price Formation with a Focus on Japan

6. Adoption, Channels, and Screening Infrastructure in Japan

7. Competitive Landscape: Companies and Platforms

8. Opportunities and Barriers for Market Participants

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures